Section of Dermatology, Rush University Medical Center; Chicago, IL.
Department of Dermatology, Indiana University School of Medicine; Indianapolis, IN.
Urology. 2022 Aug;166:164-169. doi: 10.1016/j.urology.2022.04.036. Epub 2022 May 10.
To describe local recurrence rates and patient-reported outcomes when Mohs micrographic surgery with cytokeratin-7 immunostains (MMS-CK7) is included in the interdisciplinary management of extramammary Paget's disease (EMPD) METHODS: A retrospective study was conducted of EMPD treated with MMS-CK7 as part of an interdisciplinary team at an academic medical center between 2009 and 2016. Local recurrence rates and patient-reported outcomes were determined by record review and patient surveys.
Twenty tumors in 19 patients were treated using MMS-CK7. After MMS-CK7 defined clear microscopic margins, 75% (15/20) of tumors underwent excision or reconstruction by a surgical colleague. Internal malignancy screening was performed by multiple specialties in 17 patients, with 1 associated malignancy of prostate cancer detected. No local recurrence was detected with a mean follow-up of 75.2 months. Most patients were satisfied with appearance (18/19, 95%) and function (16/19, 84%) after surgery.
Interdisciplinary teams that include MMS-CK7 can treat EMPD with low local recurrence rates, high patient satisfaction, and thorough internal malignancy screening.
描述当Mohs 显微描记术联合细胞角蛋白 7 免疫染色(MMS-CK7)用于跨学科治疗乳房外派杰病(EMPD)时的局部复发率和患者报告的结果。
对 2009 年至 2016 年期间在学术医疗中心由跨学科团队采用 MMS-CK7 治疗的 EMPD 进行回顾性研究。通过病历回顾和患者调查确定局部复发率和患者报告的结果。
19 例患者的 20 个肿瘤采用 MMS-CK7 进行治疗。在 MMS-CK7 确定明确的显微镜下切缘后,75%(15/20)的肿瘤由外科同事进行切除或重建。17 例患者接受了多个专业的内部恶性肿瘤筛查,发现 1 例前列腺癌相关恶性肿瘤。在平均随访 75.2 个月后未发现局部复发。大多数患者对手术后的外观(19 例中有 18 例,95%)和功能(19 例中有 16 例,84%)感到满意。
包括 MMS-CK7 的跨学科团队可以用低的局部复发率、高的患者满意度和彻底的内部恶性肿瘤筛查来治疗 EMPD。